Visgenx

Visgenx is developing therapeutics for dry Age-Related Macular Degeneration, a condition with no approved products, that affects over 150 million individuals worldwide and is one of the leading causes of loss of vision.  Our products in development include a fast to market approach using a repurposed drug and follow-on gene therapy solutions.